This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

ITM EANM SYMPOSIUM

  • Sunday, October 5th
  • 13:30 – 14:30
  • Room 114
  • Refreshments available

EANM 2025

SSTR-Targeting Theranostics in NETs and Beyond: Milestones and New Frontiers

Learn more about the development and emerging clinical role of investigational 177Lu-edotreotide in the treatment of neuroendocrine tumors (NETs), focusing on its scientific origins and current evidence supporting its use in gastroenteropancreatic NETs. Additionally, the session will explore future directions in SSTR-targeted therapies.

  • Sunday, October 5th
  • 13:30 – 14:30
  • Room 114
  • Refreshments available

SYMPOSIUM HOST:
Prof. Ken Herrmann, M.D., MBA

Nuclear Medicine,
University Clinic Essen, Essen, Germany

Speakers

FROM CONCEPT TO CLINIC: THE ORIGINS OF 177LU-EDOTREOTIDE IN NETS

Prof. Vikas Prasad, M.D., PhD

Nuclear Medicine,
Mallinckrodt Institute of Radiology,
St. Louis, USA

TRANSLATING EVIDENCE INTO PRACTICE: THE ROLE OF 177LU-EDOTREOTIDE IN NETS

Dr. Rocío García-Carbonero, M.D., PhD

Medical Oncology,
University Hospital 12 de Octubre,
Madrid, Spain

EXPLORING THE FUTURE OF THE SSTR-TARGETING LANDSCAPE

Prof. Damian Wild, M.D., PhD

Nuclear Medicine,
University Hospital Basel,
Basel, Switzerland